https://www.selleckchem.com/pr....oducts/3-aminobenzam
WBRT was associated with improved median OS (8.0 months, range 1.4-62.3 months) compared with supportive care only (3.3 months, range 0.7-18.3 months) (HR 0.39, 95% CI 0.20-0.75, p = 0.005). Among patients who received WBRT, higher radiation dose to the whole brain was not associated with survival (p = 0.1, but higher radiation dose to the gross tumor was associated with improved survival (p = 0.007). CONCLUSION Patients with PCNSL who are ineligible for systemic therapy may still benefit from WBRT with improvement in surviva
Like
Comment
Share
